Protein Summary
Plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN. Cleaves triple helical collagens, including type I, type II and type III collagen, but has the highest activity with soluble type II collagen. Can also degrade collagen type IV, type XIV and type X. May also function by activating or degrading key regulatory proteins, such as TGFB1 and CTGF. Plays a role in wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. Required for normal embryonic bone development and ossification. Plays a role in the healing of bone fractures via endochondral ossification. Plays a role in wound healing, probably by a mechanism that involves proteolytic activation of TGFB1 and degradation of CTGF. Plays a role in keratinocyte migration during wound healing. May play a role in cell migration and in tumor cell invasion. This gene encodes a member of the peptidase M10 family of matrix ...more
- ENST00000260302
- ENSP00000260302
- ENSG00000137745
- CLG3
- MDST
- MANDP1
- MMP-13
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
protein domain | 1 | ||
biological term | 0.98 | ||
gene perturbation | 0.85 | ||
chemical | 0.82 | ||
disease | 0.76 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1951.25 (req: < 5)
Gene RIFs: 310 (req: <= 3)
Antibodies: 971 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1951.25 (req: >= 5)
Gene RIFs: 310 (req: > 3)
Antibodies: 971 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 13
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 2180
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0